Rachel Klemovitch, Assistant Editor02.14.24
Current data from IlluminOss Medical subsidiary, ABL Medical shows that blue light with fiber-optic technology can be adapted for antimicrobial use.
IlluminOss Medical began offering a bule light fiber-optic catheter system in 2018. The system was used to harden light-curing liquid with balloon-like orthopedic implants.
Laboratory data has shown fiber-optic technology delivers specific frequencies of antimicrobial blue light that may be utilized for catheters, endotracheal tubes, and similar medical equipment. However, diverse bacterial species react differently therefore, some pathogens may be more or less affected.
Blue light inactivates pathogens by exciting oxygen-transportation molecules which overproduce unstable oxygen compounds. These reactive oxygen species break apart basic cell building blocks, including DNA bonds. The microbe cells cannot then defend themselves or develop resistance.
The system ABL is developing uses a unique patented light source and optical delivery system that has multiple frequencies of light delivered through a single wire. ABL’s technology may allow blue light to be safely delivered to anatomic locations where treatment could not be applied before.
Unlike existing systems that emit light from a single point source, ABL uses a multifrequency system that includes an optical fiber that can circumferentially and evenly emit blue light in a catheter or cannulated medical instrument.
ABL has issued multiple patents for this system. Is efficacy in fighting bacteria has been presented at two major 2023 meetings, including the American Society of Microbial conference and the European Congress of Clinical Microbiology and Infectious Diseases.
IlluminOss Medical began offering a bule light fiber-optic catheter system in 2018. The system was used to harden light-curing liquid with balloon-like orthopedic implants.
Laboratory data has shown fiber-optic technology delivers specific frequencies of antimicrobial blue light that may be utilized for catheters, endotracheal tubes, and similar medical equipment. However, diverse bacterial species react differently therefore, some pathogens may be more or less affected.
Blue light inactivates pathogens by exciting oxygen-transportation molecules which overproduce unstable oxygen compounds. These reactive oxygen species break apart basic cell building blocks, including DNA bonds. The microbe cells cannot then defend themselves or develop resistance.
The system ABL is developing uses a unique patented light source and optical delivery system that has multiple frequencies of light delivered through a single wire. ABL’s technology may allow blue light to be safely delivered to anatomic locations where treatment could not be applied before.
Unlike existing systems that emit light from a single point source, ABL uses a multifrequency system that includes an optical fiber that can circumferentially and evenly emit blue light in a catheter or cannulated medical instrument.
ABL has issued multiple patents for this system. Is efficacy in fighting bacteria has been presented at two major 2023 meetings, including the American Society of Microbial conference and the European Congress of Clinical Microbiology and Infectious Diseases.